J Pediatr Infect Dis 2017; 12(04): 214-221
DOI: 10.1055/s-0037-1603500
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Visceral Leishmaniasis in Children: Diagnosis, Treatment, and Prevention

Anil Kumar Gupta1, Amit Singh1, Saumya Srivastava1, Prem Shankar1, Sarman Singh1
  • 1Division of Clinical Microbiology and Molecular Medicine, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India
Further Information

Publication History

17 October 2016

22 November 2016

Publication Date:
08 June 2017 (eFirst)

Abstract

Leishmaniasis is a neglected tropical parasitic disease caused by an obligate intracellular protozoan of the genus Leishmania. The disease is transmitted by the bite of infected sand flies (Phlebotomus species) and affects all ages and both genders. Nearly half of the visceral leishmaniasis (VL) cases occur in children. The clinical manifestations of pediatric leishmaniasis may be different from the adults associated with host-related factors. In this review, only the visceral form is covered. Confirmation of diagnosis is made by the parasitological, immunological, or by molecular methods. Sodium antimony gluconate (stibogluconate) has been the drug of choice for more than 60 years. However, in last three decades, its efficacy against leishmaniasis has gone significantly down especially in the Indian subcontinent where most cases of VL are seen. Therefore, other drugs, such as pentamidine-isothionate, paromomycin, amphotericin B, and miltefosine, are being used as alternative drugs for VL treatment. In the absence of an effective vaccine for VL, control measures are based on the prevention of disease transmission via vector control and community awareness. The present review focuses on the current state of the leishmaniasis, its diagnosis, treatment, and prevention with emphasis on pediatric leishmaniasis.